These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15552625)

  • 1. MI risk prompts rofecoxib withdrawal.
    Thompson CA
    Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625
    [No Abstract]   [Full Text] [Related]  

  • 2. Why do COX-2 inhibitors increase risk of cardiovascular events?
    Frankish H
    Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978344
    [No Abstract]   [Full Text] [Related]  

  • 3. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
    Zeidler H
    MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521
    [No Abstract]   [Full Text] [Related]  

  • 4. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).
    Carné X; Cruz N
    Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merck withdraws arthritis drug worldwide.
    Singh D
    BMJ; 2004 Oct; 329(7470):816. PubMed ID: 15472245
    [No Abstract]   [Full Text] [Related]  

  • 7. Probable rofecoxib-induced thrombocytopenia.
    Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
    Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
    [No Abstract]   [Full Text] [Related]  

  • 8. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure.
    Ofran Y; Bursztyn M; Ackerman Z
    Am J Gastroenterol; 2001 Jun; 96(6):1941. PubMed ID: 11419859
    [No Abstract]   [Full Text] [Related]  

  • 9. [A new pharmacological principle is effective--rofecoxib. Specific COX-2 inhibition].
    MMW Fortschr Med; 1999 Dec; 141(51-52):66-7. PubMed ID: 10949630
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.
    Lenzer J
    BMJ; 2005 Feb; 330(7489):440. PubMed ID: 15731142
    [No Abstract]   [Full Text] [Related]  

  • 11. Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors?
    Ortiz E
    J Manag Care Pharm; 2004; 10(6):551-4. PubMed ID: 15548128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vioxx risk could signify trouble in class.
    Frantz S
    Nat Rev Drug Discov; 2004 Nov; 3(11):899-901. PubMed ID: 15558856
    [No Abstract]   [Full Text] [Related]  

  • 13. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclooxygenase inhibition: between the devil and the deep blue sea.
    Hawkey CJ
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?].
    Scheen AJ
    Rev Med Liege; 2004 Oct; 59(10):565-9. PubMed ID: 15623076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
    Howes LG; Krum H
    Drug Saf; 2002; 25(12):829-35. PubMed ID: 12241124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthritis. Should you be taking a COX-2 inhibitor?
    Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695
    [No Abstract]   [Full Text] [Related]  

  • 18. Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib.
    Meyer Ch; Gähler R
    Lancet; 2002 Oct; 360(9339):1100. PubMed ID: 12384019
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor.
    Wahba AL; Soper C
    Nephron; 2001 Oct; 89(2):239. PubMed ID: 11549912
    [No Abstract]   [Full Text] [Related]  

  • 20. The coxibs, selective inhibitors of cyclooxygenase-2.
    Killen JP
    N Engl J Med; 2001 Dec; 345(23):1708; author reply 1709. PubMed ID: 11759656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.